FDA has published guidance to assist sponsors preparing to 

 (ANDAs) and prior approval supplements (PASs) to ANDAs for which the applicant is seeking approval of a new strength of the drug product. The guidance describes what should be included in an ANDA and highlights serious deficiencies that may cause FDA to refuse to receive an ANDA. A refuse-to-receive decision indicates that FDA has determined that an ANDA is incomplete on its face, usually because of omissions. 

Development

News

Process Validation

Quality/GMPs

Regulatory Authority Actions

FDA publishes guidance on ANDA submissions.